Medications used for diabetes and weight loss — including Ozempic, Wegovy, Mounjaro, and Zepbound —
have been linked to a significantly increased risk of non-arteritic anterior ischemic optic neuropathy (NAION),
a serious eye condition that can lead to permanent vision loss or blindness.
Recent medical studies suggest that manufacturers Novo Nordisk and Eli Lilly may have failed to adequately
warn patients and doctors about these risks. Individuals who developed NAION or sudden vision loss after taking GLP-1
medications may be eligible for compensation.
Open and accepting new clients.
Lawsuits allege that GLP-1 receptor agonists prescribed for diabetes and weight loss increase the risk of NAION and other serious injuries. Claims focus on whether drugmakers failed to properly warn patients about vision loss risks.
NAION is caused by reduced blood flow to the optic nerve. There is currently no proven treatment to reverse the damage once it occurs, making the condition life-altering for many patients
All information is encrypted and confidential
We have been helping clients across the United States for decades.
We are highly praised and recommended by past clients.
We have a long track record of winning settlements and verdicts.
Because of the sensitivity of the case we will be addressing with you, all names and information will be kept in the strictest confidence at all times. If you or a loved one took GLP-1 Drug (Such as Ozempic, Mounjaro, or Wegovy) and later experienced serious side effects or health complications, you may be eligible for compensation.





Not available in all states. The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation. We are not affilaited with Facebook. This is an advertisement.
This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship.